Every compound, graded on what the evidence can actually carry

A PTHrP-based anabolic peptide for osteoporosis, with labelling extended to men at high fracture risk.

An approved melanocortin implant for a rare light-sensitivity disease — not a tanning drug, whatever the internet says.

The internet's favourite healing peptide: a mountain of rodent data and almost no controlled human evidence.

Evidence is mostly preclinical

An FDA-approved melanocortin agonist for one specific sexual-health diagnosis — endlessly mis-sold as a general performance enhancer.

A long-acting amylin analogue, mostly studied in combination with a GLP-1 agonist.

A salmon-derived hormone peptide once common in bone disease, now used more narrowly after regulators weighed modest benefit against a debated malignancy signal.

A long-acting oxytocin analogue approved in many countries — but not the US — to prevent uterine atony after delivery.

The other widely used GnRH antagonist in assisted reproduction protocols.

A long-acting GHRH analogue abandoned after early human studies — it reliably raises growth hormone, but the outcomes it is sold for were never tested.

A GnRH antagonist approved for advanced prostate cancer — hormone suppression without the initial flare.

A V2-selective vasopressin analogue approved in nasal, oral and injectable formulations — each tied to its own specific indications.

A neuropeptide named for a sleep effect first described in the 1970s that decades of follow-up have never clearly replicated in humans.

Evidence is mostly preclinical

The first HIV entry inhibitor — a 36-amino-acid peptide that blocks viral fusion.

Longevity claims built on an old, narrow and largely unreplicated body of research.

Evidence is mostly preclinical

The first GLP-1 receptor agonist — born from Gila-monster venom peptide biology — with formulations ranging from twice-daily to weekly injection.

A GnRH antagonist used in assisted reproduction to time ovulation precisely.

Decent cosmetic evidence on the skin, very different question when people inject it.

One of the original growth-hormone secretagogue peptides — real pharmacology, no approved physique indication, and formal FDA compounding safety concerns.

Evidence is mostly preclinical

The older sibling of GHRP-2, with historical human pharmacology but no approved indication and a notable appetite-stimulating effect.

Evidence is mostly preclinical

The body's own counter-insulin hormone, available as approved injection and nasal rescue products — another proof that 'nasal peptide' is not shorthand for experimental.

A GnRH agonist delivered as a small implant under the skin of the abdomen, suppressing sex hormones in prostate and breast cancer and certain gynaecological conditions.

A GnRH-agonist implant approved for central precocious puberty, releasing peptide continuously for about a year per implant.

A synthetic decapeptide that blocks bradykinin B2 receptors, approved for acute attacks of hereditary angioedema in adults.

A selective growth hormone secretagogue discontinued after its trials missed their endpoints — now sold for physique and recovery claims no trial ever tested.

Evidence is mostly preclinical

A fragment of the body's own reproductive signalling peptide, studied in human physiology research but not an approved therapy.

A three-amino-acid fragment of alpha-MSH marketed for gut healing and inflammation, with no human clinical studies identified by the FDA.

Evidence is mostly preclinical

A long-acting somatostatin analogue with pivotal-trial evidence for slowing tumour progression in certain neuroendocrine tumours.

A GnRH agonist whose depot injections switch off sex-hormone production — used in prostate cancer, endometriosis and central precocious puberty depending on the product.

A 14-amino-acid peptide swallowed as a capsule that works locally on the gut lining — approved oral proof that not every peptide is digested into uselessness.

The older once-daily GLP-1 agonist, with long real-world follow-up and modest effect sizes.

A once-daily GLP-1 receptor agonist for glycaemic control in type 2 diabetes — shorter-acting than the weekly agents that dominate headlines.

A GLP-1/glucagon dual agonist developed largely in Chinese trial populations.

A synthetic melanocortin peptide sold for tanning — unapproved everywhere, and routinely confused with genuinely approved melanocortin medicines.

Evidence is mostly preclinical

A mitochondrial-derived peptide with genuinely interesting biology and thin translational data.

Evidence is mostly preclinical

A GnRH agonist that has been an approved nasal-spray medicine for decades — the standing rebuttal to 'nasal peptide means research chemical'.

The foundational somatostatin analogue, used for acromegaly and symptom control in certain neuroendocrine tumours.

The natural nonapeptide hormone of labour and lactation, long approved as an IV/IM obstetric medicine.

A broader-spectrum somatostatin analogue approved for specific endocrine disorders including Cushing's disease.

A 16-amino-acid oral peptide modelled on the natural gut hormone uroguanylin, approved for chronic constipation and IBS-C in adults.

A synthetic amylin analogue approved as an add-on in insulin-treated diabetes.

An investigational GIP/GLP-1/glucagon triple agonist in an advanced Phase 3 metabolic programme.

A synthetic heptapeptide related to tuftsin, marketed online for anxiety despite no regulatory approval and almost no independent human evidence.

Evidence is mostly preclinical

A GLP-1 receptor agonist with one of the largest clinical trial programmes in modern metabolic medicine.

A synthetic heptapeptide derived from an ACTH fragment, registered as nasal drops in Russia and heavily marketed elsewhere as a nootropic.

Evidence is mostly preclinical

An MC4R agonist approved for specific genetic obesity syndromes — precision medicine, not a general weight-loss drug.

A mitochondria-targeting peptide with a narrow accelerated approval and a much broader set of unproven anti-ageing claims.

A genuine biological protein with real research history, and a separate online product that is not quite the same thing.

Evidence is mostly preclinical

A GLP-2 analogue that helps people with short bowel syndrome reduce dependence on intravenous nutrition.

A parathyroid-hormone fragment that builds bone — one of the few anabolic osteoporosis treatments.

A vasopressin analogue approved intravenously for hepatorenal syndrome — with a boxed warning about serious or fatal respiratory failure.

An approved medicine for one specific indication, routinely marketed for a much broader one.

A thymic immune peptide approved in dozens of countries for specific indications, but never approved in the US — and marketed far beyond any approval.

A dual GIP and GLP-1 receptor agonist with strong Phase 3 weight and glycaemic data.

A long-acting GnRH agonist depot used in prostate cancer and central precocious puberty.

The body's own antidiuretic nonapeptide, used intravenously in intensive care to support blood pressure in vasodilatory shock.

A cone-snail-venom-derived peptide painkiller given directly into spinal fluid for severe chronic pain.